Bio-Rad Laboratories Inc (BIO) Annual Income Statement (USD)
BIO Quarterly Financials (USD)
Frequently Asked Questions About Bio-Rad Laboratories Inc (BIO) Stock
Bio-Rad Laboratories Inc's (BIO) last reported annual revenue was USD 2.67 Billion.
Bio-Rad Laboratories Inc's (BIO) annual revenue growth rate based on the revenue reported in the past 5 years is : -1.78%
Bio-Rad Laboratories Inc's(BIO) is not profitable as of its last reported annual financials.
The net profit margin for Bio-Rad Laboratories Inc's(BIO) from its laster reported year is -23.86%
The return on equity (ROE) for Bio-Rad Laboratories Inc's(BIO) from its last reported annual financials is : -9.79%
The return on assets (ROA) for Bio-Rad Laboratories Inc's(BIO) from its last reported annual financials is : 1.86%
The return on invested capital (ROIC) for Bio-Rad Laboratories Inc's(BIO) from its last reported annual financials is : 5.31%
The Debt to Equity ratio for Bio-Rad Laboratories Inc's(BIO) from its last reported annual financials is : 13.72%
The dividend yield for Bio-Rad Laboratories Inc's(BIO) from its laster reported year is 0.00%
Bio-Rad Laboratories Inc's(BIO) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BIO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
